BACKGROUND: Personal digital assistants (PDAs) allowhealthcare professionals to checkfor potential drug-<:lrug interactions (DOIs) at the point of care, reducing the need to consulttraditional references. However, PDAscan only be as effective as the software programs they use.
A drug interaction is defined as "the pharmacological or clinicalresponse to the administration of a drug combination different from that anticipated from the known effects of the 2 agents whengivenalone."! There is potential for a drug-drug interaction (001) to occur any time a patient consumes at least2 drugs. In the US, it is not uncommon for a patient to be treated by several specialists and prescribed multiple medications, leading to a greaterpossibility of a 001. A retrospective study of prescriptions in community pharmacies indicated that 4-6% of the prescriptions dispensed could have caused an interaction.s-' The magnitude of this problem is seen in the number of Author information provided at the endof the text.
deaths that occur annuallyfrom medication errors. Medication errors, including ODIs, have been estimated to accountfor 7000 deaths annually,'
In the age of technology, personal digital assistants (POAs)allow healthcare professionals to check for potential DOIs at the point of care, reducingthe need to consult traditional reference booksor package inserts. However, as convenientas PDAs may be, they can only beas effective as the software programs they use. Withan ever-increasing numberof healthcare professionals using PDAsas drugreference tools, it is vital that the software be sensitive and specific in providing information relating to potential OOls.
In a study of the performance of community pharmacy computer software,Hazletet al. s concludedthat one-third of the software assessed was inadequate in detecting clini-cally significant DDIs. 1\velve community pharmacy software programs were evaluated using 6 fictitious patient profiles developed by the authors. Thirty-seven potential DDIs existed in the patient profiles. Of the potential DDIs, 16 were considered to be clinically significant. The clinically significant interaction pairs were determined by 2 of the authors (Hansten and Horn) to "assess the sensitivity and specificity of software in detecting well-documented, clinically important, contemporary DDIs." The authors concluded that the overall sensitivity (ability to detect an important interaction) ranged from 0.44 to 0.88, with an average of 0.71 , while specificity (the ability to avoid detecting non-interactions) ranged from 0.71 to 1.0, with an average of 0.89.
Another study assessed the ability of PDA software in detecting clinically relevant DDIs. ' May 6, 2003) . Sensitivity, specificity, and positive and negative predictive values were determined for these programs using 40 clinically important and 40 clinically unimportant DDIs. The author concluded that iFacts and Lexi-Interact were exceptional programs in regard to accuracy, comprehensiveness, and ease of use.
The purpose of this study was to further evaluate the ability of DOl software programs for Palm OS-compatible PDAs to detect clinically important DDIs. (Table 1) . 5 In the years since publication of the Hazletstudy. cisapride has been taken offthemarket. Because of this,thepatient profiles weremodified. A groupof 3 pharmacy faculty members and3 PharmD students metto assignmedications to replace cisapride. In thefirst profile, ergotamine tartrate withcaffeine I mgwasused. In thesecond instance, pimozide 1mg tablets replaced cisapride. These substitutions were justified because the cisapride--erythromycin interactions are in the same drug interaction class (substrate of CYP3A) as theergotamine-erythromycin andpimozide-erythromycin interactions. Unlike theHazlet study of computer software. patient information suchas age,sex.anddisease state wasnotentered intothe programs dueto theinability of thePDAprograms to holdsuchdata. In the profiles,37 potential DOIsexisted. Of these, 16 were considered clinically important and 21 clinically unimportant. All softwareanalyzed allowedeach of the drug pairs from each of the patientprofilesto be entered and checked for OOls. One of the authors (Perkins)entered each profile in the same order intoeach programevaluated. The number of true positives, false negatives, false positives, and true negatives were recorded on a data collection form.
Methods
Sensitivity, specificity, and negative and positive predictive values were determined for each software program. A true positive occurred when a clinically important DOl was identified. A false negative occurred when a clinically significant interaction was not identified but should have been. A true negativeoccurredwhen a clinicallyunimportant DOl was not identified,and a false positive occurred when a DOl was identified but was not considered clinically significant.
Sensitivity Results Table 2 provides the results for sensitivity, specificity, and positive and negative predictive values. The average sensitivity and specificity of the 8 programs were 0.95 and 0.78, respectively. The overall PPVs and NPVs were 0.80 and 0.97, respectively. Five of the programs scored perfectlyon sensitivity. The ePocrates programs scored highest in specificity, while Lexi-Interact and the Tarascon pocket Pharmacopoeia scored considerably lower. The only pro-gram that scored perfectly in specificity was Mosbylx; however, it received the lowest score in regard to sensitivity. The only programs that scored 90% or greater on both sensitivity and specificity were the ePocrates programs. NPV was generally high for all the programs (>0.88), while PPV varied considerably (0.62-1.0).
Of the 37 drug pairs analyzed, only one program was unable to analyze all of the drug pairs. This was due to an omission of ergotamine or a brand equivalent in the mo-bileMICROMEDEX database. This omission prevented it from achieving a sensitivity of 1.0.
Six false negatives and 34 false positives were identified ( Table 3 ). All 8 programs correctly identified 18 of the pairs as being important or unimportant. Discrepancies occurred for 19 pairs.
Discussion
To provide high quality health care, all healthcare providers who prescribe and/or dispense medications must catch prescribing errors prior to the patient receiving the medication. Detecting DOIs is an integral part of this responsibility. Many studies have assessed pharmacists' ability to detect DOIs and respond to 001 alerts. For example, Weideman et at.' found that only 66% of pharmacists who did not have computer assistance detected all of a group of DDIs presented to them. Cavuto et aL8 found that, when presented with 2 prescriptions resulting in a potentially fatal 001. only 68% of computer-assisted pharmacists intervened by not allowing the prescriptions to be filled. This study prompted hypotheses as to why a pharmacist with a computerized screening program would not take action to prevent a potentially serious 001. One suggestion was that outdated software and the plethora of false positives produced rendered screening program warnings easy to ignore,"
Since some clinically important DDls were not detected by one-third of the computer programs evaluated in the Hazlet et al. s study, inadequately performing software may A retrospective analysis was conducted of pharmacists' actions after receiving drug utilization review alerts, approximately 10% of which were DOl alerts." The authors found that, in 43% of the cases, pharmacists responded to the DOl alert by using their own references, an indication that the alerts were not providing sufficient or high-quality information about the DDI.
Segments of the healthcare community have increasingly embraced PDAs because of their compactness and ability to provide quick access to vital information at the point of care. Health professionals are increasingly relying on PDAs, which can be updated frequently, for accessing drug information, performing calculations, tracking patients, e-prescribing, and organizing general information.
Traditionally, pharmacists have used computers and drug compendia as reference tools. With the advent of PDAs, more pharmacists are turning to this pocket-sized device that provides information on DDIs, particularly outside of community pharmacy settings where computer access is generally easy. It is important that these tools be dependable and accurate. Each of the PDA programs that we evaluated had a differing scope of information and number of drugs in their databases. Although this might impact the utility of the programs for other uses, it was not the purpose of this study to determine such utility.
PDAs are often used for general drug information, and the value of the information in decision support likely affects actual use. Approximately 3000 physicians and medi-Performance of Drug-Drug Interaction Softwarefor Personal DigitoJ Assistants cal students were surveyed regarding their experience with ePocrates software." Of the 29% who responded, 60% used the software more than 2 times per day, 92% reported that it reduced their use of other drug references, and 50% reported avoiding dispensing drugs that could produce serious adverse reactions on one or more occasion per week through use of the software.
As more drugs appear on the market, the potential for DOIs increases. Although it is unlikely that all potential DOIs will lead to patient harm, it is imperative that software identify clinically important interactions. With one in 5 physicians using PDAs as of 2004 and a higher percentage of use expected in the future, it is crucial that the software programs be reliable."
Enders et al." compared the breadth of coverage and clinical dependability of 9 drug information PDA software programs: Lexi-Drugs Platinum, Tarascon ePharmacopoeia, Mosby's, ePocrates Rx, Davis's Drug Guide for Physicians (DrDrugs), PDR 2001, Physicians Drug Handbook, A to Z Drugs, and mobileMICROMEDEX. Fiftysix questions were developed to assess each program, 4 of which related to DOIs. LexiComp Platinum provided the greatest breadth of information (75%). It was also considered 100% clinically dependable compared with a minimum of2 drug resources. MobileMICROMEDEX provided the least breadth (32.1 %) and was the least clinically dependable (66.7%).
Of the 8 programs evaluated in our study, 2 were available at no cost. ePocrates Rx was available for download at no charge to anyone with a PDA, while mobileMI- Table 3 . Drug-Drug Pairs: Discrepancies Between Programs" Tarascon Totals   1  TP  TP  TP  TP  FN  TP  TP  1 FN  5  TP  TP  FN  TP  TP  FN  TP  2FN  9  FP  TN  TN  FP  FP  TN  FP  4FP  11  TP  TP  TP  TP  TP  FN  TP  1 FN  13  TN  TN  TN  FP   TN   TN  TN  1 FP  14  TN  TN  TN  FP  FP  TN  TN  2FP  15  TN  TN  TN  FP  TN  TN  FP  2FP  16  TP  TP  FN  TP  TP  FN  TP  2FN  18  TN  TN  TN  TN  TN  TN  FP  1 FP  20  FP  TN  TN  FP  FP  TN  FP  4FP  21  TN  FP  TN  FP  FP  TN  FP  4 FP  23  TN  TN  FP  TN  TN  TN  FP  2 FP  28  FP  TN  TN  TN  FP  TN  FP  3 FP  29  TN  TN  TN  TN  TN  TN  FP  1FP  30  FP  TN  TN  TN  TN  TN  FP  2 FP  31  FP  TN  TN  FP  FP  TN  FP  4 FP  35  TN  TN  TN  FP  TN  TN  TN  1 FP  36  TN  FP  TN  FP  TN  TN  TN  2 FP  37  TN  TN  TN  FP  TN  TN  TN  1 CROMEDEX was available for download to all healthcare professionals associated with an institutional subscription. The remaining programs rangedfrom $27 to $75 per year at the time of the study.Cost was primarilyrelated to the availability of color on the screen and was not a factor in the programs' ability to detect clinically relevant DOIs. The free programs were the only ones without color. Of the programs evaluated, several were general drug databases with the added ability to check for drug interactions (ePocrates Rx, ePocrates Rx Pro, mobile-MICROMEDEX).The remaining programs were developed solely for the purpose of checking for drug interactions (DrugIx, iFacts, Lexi-Interact, the Tarascon pocket Pharmacopoeia, MosbyIx). Of the programs that accurately detected all 16clinically relevantDOIs, 3 were general databases (ePocrates Rx, ePocrates Rx Pro, the Tarascon pocket Pharmacopoeia), while 2 were exclusivelyfor the assessment ofDOIs (iFactand Lexi-Interact).
Drug Pair Druglx ePocrates IFacts Lexl-Interact Mlcromedex Mosbylx
In addition to identifying DOIs,eachprogram furnished a mechanism for the interaction and a management strategy. Halfprovided information on theseverity andonset of theinteraction (iFacts, Lexi-Interact, mobileMICROMEDEX MosbyIx). While 3 programs (iFacts, Lexi-Interact, mobileMICROMEDEX) supplied a level of evidence, only iFacts and Lexi-Interactprovided and discussed the references given. The maximum number of medications that could be entered into the programs ranged from 16 (iFacts) to no limitas long as adequate memory was available (Lexi-Interact, the Tarascon pocketPharmacopoeia).
When Barrens" evaluatedthe abilityof 9 drug-drug interaction software programs for PDAs to correctly identify 80 DOl pairs, he concluded that iFacts and Lexi-Interact excelled when taking into account ease-of-use, comprehensiveness, and accuracy. After omitting the ease-of-use and comprehensiveness scores and focusing on accuracy, the highest accuracy scores, defined as the sum of values obtainedfor sensitivity, specificity, PPV,and NPV multiplied by 100, were computed for iFacts and mobile-MICROMEDEX. The limitation of this accuracy score is in the assumption that sensitivity is as important as specificity or the PPV and NPV. While important,a program's specificitymay not lead to harm as readily as missing an important interaction and thus should perhaps not be weighted equally to sensitivity. In the case of detecting DOIs, being overly cautious is preferred. Barrons found Clinical Pharmacology OnHand to be the most sensitive (l.0), followed by iFacts and Lexi-Interact (0.98),and then mobileMICROMEDEX (0.95). The specificity of the programs ranged from 1.0 (mobileMICROMEDEX) to 0.75 (Clinical Pharmacology OnHand).
If Barrons' accuracy score was assigned to the 8 programs that we analyzed, the ePocrates programs would rank highest (379),followed by MosbyIx (369) and iFacts (367). Barrons found iFacts,mobileMICROMEDEX, and Lexi-Interact to have the highestaccuracy scores,perhaps becausethey were the Palm OS versions of the references used (eFacts and Micromedex DRUG-REAX)to formulate the DDI pairs in the study. There were many differences in the included drug pairs used to assess the programsbetween Barrons' and our study.
Limitations
We assumed that the substitutions for cisapride were justifiable because the cisapride--erythromycin interactions are in the same interaction class(CYP3A substrates) as the ergotamine--erythromycin and pimozide--erythromycin interactions. Because the methodologyin the Hazlet et al. 5 study was used as a template,comparingour results with theirs is hampered, although the most important difference is that Hazlet compared computer systems whilewe evaluated PDA software. Companies producing software for computers and PDAs usually update the programs fairly frequently. Thus, these results represent a snapshot in time. Not all possible PDA programs were evaluated, so there may be othersthatoutperform the 8 evaluated in this study. Otherprograms and new versions of the ones that we analyzed should be periodically evaluated to determine their utility for the assessment of DOIs.
Conclusions
Examination of the ability of 8 DOl software programs available for PDAs showed that ePocrates Rx and ePocrates Rx Pro performed the best in sensitivity and specificity.Although highly sensitive, it is likely that no program will catch every potential DOl and it would behoove healthcare professionals to be aware of programs that consistently perform best.In addition to ePocrates Rx, Lexi-Interact should be consideredfor its concise discussionof the available references.
Because evaluation of any program is a point-in-time determination and vendors are constantly striving to update and improvetheir products, programs shouldbe periodically evaluated in head-to-head comparisons. 
